Oncternal Therapeutics, Inc. (ONCT)

$0.97

+0.02 (+1.98%)
Rating:
Recommendation:
-
Symbol ONCT
Price $0.97
Beta 1.443
Volume Avg. 0.25M
Market Cap 54.647M
Shares () -
52 Week Range 0.69-3.11
1y Target Est -
DCF Unlevered ONCT DCF ->
DCF Levered ONCT LDCF ->
ROE -52.56% Strong Sell
ROA -53.62% Strong Sell
Operating Margin -
Debt / Equity 11.13% Neutral
P/E -1.36 Sell
P/B 0.77 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ONCT news


Dr. James Breitmeyer
Healthcare
Biotechnology
NASDAQ Capital Market

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.